(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 196.6MM | +2% |
Operating Income | -31.4MM | -48% |
Operating Expenses | 228MM | - |
Net Income | -31.2MM | -49% |
R&D | 21MM | -12% |
G&A | 144.4MM | +6% |
Amortization | 10.8MM | +1% |
Interest Expense | 900K | -10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
INCY vs. MYGN: Which Stock Is the Better Value Option?
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast CancerSALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk Survey: Breast Cancer Edition, which revealed that a majority (63%) of women do not know that there is an increased risk of breast cancer for women with dense breast
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testin
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers Myriad’s groundbreaking platform MRD technology, which enable
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it’s a Great Place To Work – 27 percentage points higher than the average U.S. company. “It’s rare to work somewhere wh
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental HealthSALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Surve
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$34.23 Current share...
Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.